4.95
price down icon1.59%   -0.08
 
loading
Schlusskurs vom Vortag:
$5.03
Offen:
$5.03
24-Stunden-Volumen:
2.88M
Relative Volume:
1.43
Marktkapitalisierung:
$1.50B
Einnahmen:
$248.37M
Nettoeinkommen (Verlust:
$11.74M
KGV:
99.00
EPS:
0.05
Netto-Cashflow:
$18.24M
1W Leistung:
-5.17%
1M Leistung:
-7.30%
6M Leistung:
-20.93%
1J Leistung:
+14.06%
1-Tages-Spanne:
Value
$4.91
$5.075
1-Wochen-Bereich:
Value
$4.89
$5.22
52-Wochen-Spanne:
Value
$3.97
$7.63

Mannkind Corp Stock (MNKD) Company Profile

Name
Firmenname
Mannkind Corp
Name
Telefon
818-661-5000
Name
Adresse
1 CASPER STREET, DANBURY, CA
Name
Mitarbeiter
407
Name
Twitter
@MannKindCorp
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
MNKD's Discussions on Twitter

Vergleichen Sie MNKD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MNKD
Mannkind Corp
4.95 1.50B 248.37M 11.74M 18.24M 0.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Mannkind Corp Stock (MNKD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-10 Eingeleitet Wedbush Outperform
2024-12-20 Eingeleitet Wells Fargo Overweight
2024-12-19 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-09-09 Fortgesetzt Leerink Partners Outperform
2024-06-13 Eingeleitet Rodman & Renshaw Buy
2023-10-10 Eingeleitet Wedbush Outperform
2021-05-14 Eingeleitet RBC Capital Mkts Sector Perform
2019-12-24 Eingeleitet Oppenheimer Outperform
2019-10-25 Eingeleitet Cantor Fitzgerald Overweight
2019-05-14 Eingeleitet BTIG Research Buy
2019-03-04 Eingeleitet SVB Leerink Outperform
2019-02-22 Eingeleitet SVB Leerink Outperform
2018-02-28 Herabstufung Maxim Group Hold → Sell
2017-11-01 Herabstufung Maxim Group Buy → Hold
2017-10-10 Eingeleitet H.C. Wainwright Buy
2017-10-06 Bestätigt Maxim Group Buy
2017-08-11 Eingeleitet Maxim Group Buy
2016-05-10 Bestätigt Piper Jaffray Underweight
2016-05-10 Bestätigt RBC Capital Mkts Underperform
2016-01-06 Bestätigt Piper Jaffray Underweight
2016-01-06 Bestätigt RBC Capital Mkts Underperform
2015-11-04 Herabstufung RBC Capital Mkts Outperform → Underperform
2015-09-09 Herabstufung Piper Jaffray Neutral → Underweight
2015-08-03 Bestätigt RBC Capital Mkts Outperform
2015-05-11 Herabstufung JP Morgan Neutral → Underweight
2015-05-11 Bestätigt MLV & Co Hold
2015-04-16 Bestätigt RBC Capital Mkts Outperform
Alle ansehen

Mannkind Corp Aktie (MNKD) Neueste Nachrichten

pulisher
Mar 21, 2025

Cantor maintains Overweight rating on MannKind stock at $9 target - Investing.com

Mar 21, 2025
pulisher
Mar 19, 2025

Why It's Worth Keeping An Eye On MannKind - RTTNews

Mar 19, 2025
pulisher
Mar 18, 2025

Inhalable Biologics Industry Report 2025: World Market to Nearly Triple in Size by 2030, Reaching $10.06 Billion at a CAGR of 17.6% - Yahoo Finance

Mar 18, 2025
pulisher
Mar 12, 2025

MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

MAC Lung Disease Market Statistics Expected to Experience Major - openPR

Mar 11, 2025
pulisher
Mar 10, 2025

MannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025 - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 - Yahoo Finance

Mar 10, 2025
pulisher
Mar 07, 2025

AllPennyStocks.com News: Companies Looking Towards Future Revenue with New Diabetes Therapies - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Commit To Purchase MannKind At $3, Earn 13.3% Using Options - Nasdaq

Mar 07, 2025
pulisher
Mar 04, 2025

Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart

Mar 04, 2025
pulisher
Mar 04, 2025

Non- Tuberculous Mycobacterial Infections Market on Track - openPR

Mar 04, 2025
pulisher
Mar 02, 2025

MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ - MSN

Mar 02, 2025
pulisher
Mar 01, 2025

MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance

Mar 01, 2025
pulisher
Feb 28, 2025

MannKind Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025
pulisher
Feb 27, 2025

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question - Seeking Alpha

Feb 27, 2025
pulisher
Feb 27, 2025

MannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025
pulisher
Feb 27, 2025

MannKind: Q4 Earnings Snapshot - mySA

Feb 27, 2025
pulisher
Feb 27, 2025

MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Re - GuruFocus.com

Feb 27, 2025
pulisher
Feb 27, 2025

MannKind Corp Q4 Earnings: EPS Meets Estimates at $0.03, Revenue Surpasses Expectations at $77 Million - GuruFocus.com

Feb 27, 2025
pulisher
Feb 27, 2025

MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

Feb 27, 2025
pulisher
Feb 26, 2025

Mannkind stock gains amid Q4 report, business update - MSN

Feb 26, 2025
pulisher
Feb 26, 2025

MannKind Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

MannKind (MNKD) Q4 Earnings Meet Estimates - Yahoo Finance

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings call transcript: MannKind Q4 2024 beats EPS forecast, stock jumps - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

MannKind earnings beat by $0.05, revenue topped estimates - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

MannKind shares move 4% higher on strong revenue growth By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

MannKind shares move 4% higher on strong revenue growth - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

MANNKIND CORP SEC 10-K Report - TradingView

Feb 26, 2025
pulisher
Feb 25, 2025

MannKind Corp (MNKD) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance

Feb 25, 2025
pulisher
Feb 24, 2025

Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance

Feb 24, 2025
pulisher
Feb 20, 2025

MannKind: Q2 Earnings Snapshot -August 07, 2024 at 08:09 am EDT - Marketscreener.com

Feb 20, 2025
pulisher
Feb 19, 2025

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 - Yahoo Finance

Feb 19, 2025
pulisher
Feb 19, 2025

MannKind Sets Stage for 2024 Performance Review: CEO and CFO to Unveil Full Year Results - Stock Titan

Feb 19, 2025
pulisher
Feb 18, 2025

MannKind (MNKD) Expected to Announce Earnings on Tuesday - MarketBeat

Feb 18, 2025
pulisher
Feb 13, 2025

Wedbush Initiates Coverage on MannKind (NASDAQ:MNKD) - MarketBeat

Feb 13, 2025
pulisher
Feb 11, 2025

MannKind To Present At Oppenheimer Healthcare Life Sciences Conference; Webcast At 11:20 AM ET - Nasdaq

Feb 11, 2025
pulisher
Feb 11, 2025

An Analysis of Mannkind Corp (MNKD)’s Potential Price Growth - Knox Daily

Feb 11, 2025
pulisher
Feb 11, 2025

MannKind (NASDAQ:MNKD) Coverage Initiated by Analysts at Wedbush - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Investing in Fortuna Mining Corp (FSM) Is Getting More Attractive - Knox Daily

Feb 10, 2025
pulisher
Feb 09, 2025

MannKind Co. (NASDAQ:MNKD) Shares Sold by Calamos Advisors LLC - MarketBeat

Feb 09, 2025
pulisher
Feb 07, 2025

There is no doubt that Mannkind Corp (MNKD) ticks all the boxes. - SETE News

Feb 07, 2025
pulisher
Feb 06, 2025

MannKind to Present at Upcoming Investor Conferences - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

MNKD Shares Experience Surge in Value - Knox Daily

Feb 06, 2025
pulisher
Feb 06, 2025

MannKind Executives Set for Strategic Presentations at Elite Healthcare Investment Forums - StockTitan

Feb 06, 2025
pulisher
Feb 04, 2025

Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex

Feb 04, 2025
pulisher
Feb 03, 2025

(02/03/25) Top Picks 2025: MannKind (MNKD) - Moneyshow.com

Feb 03, 2025
pulisher
Feb 02, 2025

MannKind Corporation's (NASDAQ:MNKD) institutional investors lost 4.0% over the past week but have profited from longer-term gains - Yahoo Finance

Feb 02, 2025

Finanzdaten der Mannkind Corp-Aktie (MNKD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Kapitalisierung:     |  Volumen (24h):